Table 4.
Subgroup analysis of severe asthma patients with refractory severe asthma with the eosinophilic–allergic phenotype associating nasal polyposis (n = 22) at baseline and after 52-week treatment with subcutaneous mepolizumab100 mg every 4-week. Nine of 22 included subjects (40.9%) associated a diagnosis of NSAID-exacerbated respiratory disease (NERD).
| Variables | Baseline | After 52-Weeks of Mepolizumab | p |
|---|---|---|---|
| ACT * | 15 ± 4.08 | 22.33 ± 4.08 | <0.0001 |
| Number of annual AEs * | 3.04 ± 1.13 | 0.53 ± 0.7 | <0.0001 |
| Use of OCS (mg/day) * | 10.21 ± 8.2 | 4.6 ± 3.9 | <0.0001 |
| Number of nasal polyp surgeries * | 1.4 ± 0.9 | 0.22 ± 0.42 | <0.0001 |
| FVC (mL) * | 3473.54 ± 866.5 | 3815.66 ± 948.45 | 0.0082 |
| FEV1 (mL) * | 2608.18 ± 746.7 | 2965.46 ± 708.79 | 0.0004 |
| FEV1% | 77.77 ± 15.53 | 85.28 ± 17.63 | 0.073 |
| SNOT-22 * | 63.75 ± 20.31 | 33.5 ± 20.92 | <0.0001 |
| FENO (ppb) | 58.9 ± 22.61 | 70.8 ± 44.77 | 0.711 |
| Eosinophils/μL peripheral blood * | 591 ± 322 | 62 ± 47.14 | <0.0001 |
| Total IgE (IU/mL) | 295.44 ± 344.05 | 325.09 ± 366.65 | 0.124 |
| sIgE D. pteronyssinus (kUA/L) | 1.71 ± 3.77 | 5.78 ± 11.59 | 0.224 |
| sIgE D. farinae (kUA/L) | 1.03 ± 2.62 | 3.8 ± 7.18 | 0.776 |
| sIgE Blomia tropicalis (kUA/L) | 0 | 0 | 0.385 |
ACT: Table 4: Asthma Control Test. Aes: Asthma exacerbations. OCS: Oral corticosteroids. FVC: Forced Ventilatory Capacity. FEV1: forced expiratory volume in the first second. SNOT-22: Sino-Nasal Outcome Test-22. FENO: Fractional exhaled nitric oxide. sIgE: Specific IgE. Mean values and standard deviation are shown. (*) Indicates statistical significance (p < 0.05).